Inherited Genetics Determine Cancer Evolutionary Paths and Risk

The Interplay of Germline Genetics and Somatic Mutations

Scientific evidence now confirms that the genetic code an individual inherits at birth fundamentally directs the trajectory of tumor development. While cancer initiates through the accumulation of DNA mutations, the specific evolutionary route a malignancy takes is not random. Instead, inherited genetics interact with acquired mutations to shape the disease's progression. This breakthrough helps clarify why individuals in identical environments face disparate oncology risks, such as why certain lifelong smokers avoid lung cancer while non-smokers may develop it.

Controlling Variables Through Genomic Diversity

To isolate genetic influence from lifestyle factors, an international team led by Professor Duncan Odom, Dr. Sarah Aitken, and Professor Martin Taylor conducted a study using four distinct mouse strains. These strains provided a level of genetic variation mirroring human populations. Researchers administered a controlled dose of the carcinogen diethylnitrosamine (DEN)—a substance found in processed foods and tobacco—to mice at 15 days old. By holding environmental exposure constant, the team removed the noise that typically complicates human epidemiological studies.

Mapping the Evolutionary Trajectory

Analysis of nearly 600 tumor genomes revealed that while most cancers eventually activated the MAPK signaling pathway to drive growth, the specific mutations used to reach that stage varied by genetic background. Key findings from the genomic sequencing included:

• Genetic background determines the specific driver mutations that trigger tumor growth.
• Certain inherited traits increase the likelihood of whole-genome duplication, where cells copy their entire chromosomal set.
• Inherited genes influence how secondary signaling pathways are modified during tumor expansion.

Professor Duncan Odom, currently at the German Cancer Research Centre (DKFZ), noted that while tumors may reach the same biological destination, the route is predetermined by the host's genetic makeup. This suggests that cancer development is less a product of chance than previously assumed.

Refining Precision Medicine and Diagnostics

These findings suggest that the future of oncology lies in integrating inherited genetic data into screening and treatment protocols. Dr. Sarah Aitken of the Yale School of Medicine emphasized that a patient's genetic background likely dictates their response to DNA-damaging therapies. Consequently, diagnostic strategies must account for population diversity to improve accuracy. Dr. Sam Godfrey of Cancer Research UK indicated that while further human studies are required, these results provide a foundation for more precise methods of intercepting and treating cancer based on individual genetic profiles.

Source: ScienceDaily